Researchers reported full results of the 5-year GAS trial, the first randomized controlled trial to assess the effects of general anesthesia in infancy on neurodevelopmental outcomes.
The FDA has granted marketing clearance for eNeura’s single-pulse transcranial magnetic stimulation (sTMS) device for use in patients ≥12 years for the acute and prophylactic treatment of migraine.
The effectiveness of only 10 of 43 available pain measurement instruments specific to neonates has been examined in studies deemed of poor to fair quality.
Childhood cancer survivors are at risk for long-term peripheral neuropathy, particularly when treated with cisplatin.
In this retrospective analysis of the Pediatric Health Information System database, investigators obtained data on pediatric hospitalizations for opioid exposure in the US between 2004 and 2015.
Researchers introduce and investigate a new category of headache termed undifferentiated headache in a pediatric population.
A recent study evaluated the prevalence of persistent pain after pediatric ambulatory surgery 1, 3 and 6 months, as well as risk factors for persistent pain.
The Food and Drug Administration is requiring that changes be made to the labeling of prescription cough and cold medicines containing codeine and hydrocodone.
Peripheral nerve blocks for pediatric headache treatment are associated with significant benefit and minimal risk.
Use of the 9-item Pediatric Pain Screening Tool may help clinicians identify children with headache who are at risk for poor outcomes, ultimately helping to optimize individualized therapy.
